Poway resident Mark Lawless attended the fourth annual “Picnic with the Chief” on July 16 to learn about fire safety for himself and his community, he said. “I’ve already complied with Zone Zero, ...

Associated Press / news@whmi.com The University of Michigan and athletic director Warde Manuel have agreed to a buyout of the ...

The launch of Novo’s Wegovy pill, which began in early January, has become a turning point in the treatment of obesity. Injectable GLP-1 medicines for weight loss have been around for nearly nine ...

Jan 14 (Reuters) - Structure Therapeutics' (GPCR.O), opens new tab CEO expects oral weight-loss pills to capture as much as half of the GLP-1 market by 2030, driven partly by pent-up demand from ...

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...

SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

Structure’s aleniglipron elicited over 11% weight loss in a Phase II trial, sending the biotech’s stock up nearly 103% as markets closed on Monday. Structure Therapeutics’ investigational oral GLP-1 ...

Good day, and thank you for standing by. Welcome to the Structure Therapeutics top line results from the aleniglipron Phase II Access Program. [Operator Instructions] Please be advised that today's ...

All exercises are completed using VS Code with the TMC extension. The structure of this repository follows the same structure as the course. Questions are not written down, because I assume that the ...

Researchers at Google Quantum AI have used their Willow quantum computer to help interpret data from Nuclear Magnetic Resonance (NMR) spectroscopy, a mainstay of chemistry and biology research. The ...

Structure Therapeutics Inc. is a clinical-stage biotech focused on oral GLP-1 drugs for obesity, targeting a rapidly growing sector in pharma market. GPCR's valuation appears attractive given a $1B ...